SCHEMBL4170305

SCHEMBL4170305

Cn1c2c(c3cc(Br)ccc31)CCCC2O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ HSD17B10 Q99714 4/20 0.49
▸ USP2 O75604 1/20 0.49
▸ HTR1A P08908 2/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ HTR7 P34969 1/20 0.44
▸ HTR6 P50406 1/20 0.44
▸ MAPT P10636 3/20 0.41
▸ PPARG P37231 1/20 0.41
▸ NCOA2 Q15596 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ ALOX5 P09917 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ TP53 P04637 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15265192 0.83 MEN1 (0.50) MEN1KMT2AHSD17B10USP2HTR1A
SCHEMBL4170291 0.79 DHODH (0.55) MEN1KMT2AHSD17B10USP2HTR1A
SCHEMBL4157194 0.74 HTR6 (0.56) MEN1KMT2AHTR1AHTR2AHTR7
SCHEMBL15278235 0.74 HTR6 (0.51) MEN1KMT2AHSD17B10USP2HTR1A
SCHEMBL12241734 0.73 ALOX5 (0.60) MEN1KMT2AHSD17B10HTR2AMAPT
SCHEMBL3861613 0.73 ALOX5 (0.65) MEN1KMT2AHSD17B10HTR2AMAPT
SCHEMBL12127612 0.72 HTR6 (0.46) MEN1KMT2AHTR6MAPTPPARG
SCHEMBL4191487 0.72 HTR1A (0.49) MEN1KMT2AHSD17B10USP2HTR1A
SCHEMBL17895753 0.72 ALOX5 (0.68) MEN1KMT2AHSD17B10HTR2AMAPT
Hydrochloric Acid SCHEMBL4156683 0.71 HTR1A (0.48) MEN1KMT2AHSD17B10USP2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 — — US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 — — US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 — — US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control VEGFA, FLT4, KDR MEN1 4608/4885KMT2A 3806/4885HSD17B10 1367/4885
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR MEN1 4608/4885KMT2A 3806/4885HSD17B10 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback